Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

1. The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose-related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occ...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: van Acker, S. A., Kramer, K., Grimbergen, J. A., van den Berg, D. J., van der Vijgh, W. J., Bast, A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 1995
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1908788/
https://ncbi.nlm.nih.gov/pubmed/7582554
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg